Migden, Michael R, Carola Berkin, Anne Lynn Chang, and Et al. “Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients With Locally Advanced Cutaneous Squamous Cell Carcinoma”. SKIN The Journal of Cutaneous Medicine 2 (December 17, 2018): S77. Accessed July 4, 2024. https://jofskin.org/33014/index.php/skin/article/view/473.